Clinical Trials at CHI Health - CHI Health, Nebraska (NE) - Southwest Iowa (IA)
What is a Clinical Trial?

A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are the fastest and safest way to find treatments that are effective in human subjects.

Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.

Clinical trials are ongoing and some may not be listed. If you have any questions please email the CHI Health Research office or call 402-343-8511.

Condition Description Disease Site
Cardiac S-ICD (Ref number:180)

S-ICD® System Post Approval Study (S-ICD PAS)

Cardiac REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) (Ref number:159)

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group STudy to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial)

Cardiac FOURIER (Ref number:174)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease

Cardiac BIOFLOW (Ref number:185)

The BIOFLOW-V trial (“A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions”) is designed to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic coronary artery lesions compared to the Xience coronary stent system.

Cardiac CIRT (Ref number:186)

A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome

Cardiac SILVER-AMI (Ref number:182)

Risk Stratification in Older Persons with Acute Myocardial Infarction: SILVER-AMI

Cardiac RE-DUAL PCI (Ref number:183)

A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI)

Cardiac ODYSSEY (Ref number:168)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Cardiac GLORIA-AF  (Ref number:162)

Boehringer Ingelheim Pharmaceuticals, Inc., “GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation” (Phase II/III)

Cardiac ABSORB (Ref number:181)

A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions

Gastroenterology Gilead Hepatitis B ( HBV) (Ref number:189)

Obsevational, post marketing renalsafety surveillance registry in subjects with chronic hepatitis B ( HBV) infection with decompensated liver disease receiving nucleotide/side therapy.

Gastroenterology Humira Legacy (Ref number:175)

Registry looking for patients with moderate to severe active ulcerative colitis who receive Humira with or without immunomodulatory therapy.

Nephrology FIDELIO (Ref number:187)

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disase

Nephrology FIGARO (Ref number:188)

A Randomized, Double-blind, placebo-controlled, parallel-group, multicenter, event driven Phase 3 study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitis and the clinical diagnosis of diabetic kidney disease in addition to standard of care.

Nephrology ROXA (Ref number:176)

Randomized, double blind, placebo, controlled study evaluating the safety and efficacy of Roxadustat for treatment of Anemia in Chronic Kidney Disease patients not on dialysis.

Oncology Lilly Lung (Ref number:177)

Protocol I3Y-MC-JPBK(a) JUNIPER: A Randomized Phase 3 Study of Abemaciclib plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy

Orthopedics Zimmer Metal on Metal Total Hip Replacement (Ref number:190)

Post market survellance study of Zimmer metal on metal hip

Type 2 Diabetes GSK Harmony (Ref number:184)

US post market requirement to evaluate the effect of albiglutide on cardovascular events in patients with Type 2 diabetes.

Women's Health BV Harmony (Ref number:173)

A phase 3, double-blind, multicentre, randomised, placebo-controlled study to determine the efficacy and safety of SPL7013 Gel (VivaGel®) to prevent the recurrence of bacterial vaginosis